

Board of Governors of the Federal Reserve System, January 21, 2005.

Robert deV. Frierson,

Deputy Secretary of the Board.

[FR Doc. 05-1428 Filed 1-25-05; 8:45 am]

BILLING CODE 6210-01-S

FEDERAL RESERVE SYSTEM

Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.*) (BHC Act), Regulation Y (12 CFR Part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The application also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States. Additional information on all bank holding companies may be obtained from the National Information Center website at www.ffiec.gov/nic/.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than February 21, 2005.

A. Federal Reserve Bank of Cleveland (Cindy C. West, Banking Supervisor) 1455 East Sixth Street, Cleveland, Ohio 44101-2566:

1. *Central Bancshares, Inc.*, Lexington, Kentucky; to acquire 100 percent of the voting shares of First Bank, Inc., Louisville, Kentucky.

2. *Commodore Financial Network, Inc.*, Somerset, Ohio; to become a bank holding company by acquiring 100 percent of the voting shares of Commodore Bank, Somerset, Ohio.

3. *Hometown Bancorp, Inc.*, Kent, Ohio; to become a bank holding company by acquiring 100 percent of the voting shares of Home Savings Bank, Kent, Ohio.

B. Federal Reserve Bank of Chicago (Patrick Wilder, Assistant Vice President) 230 South LaSalle Street, Chicago, Illinois 60690-1414:

1. *Freedom Bancshares, Inc.*, Sheldon, Iowa; to become a bank holding company by acquiring 100 percent of the voting shares of Freedom Bank, Sheldon, Iowa (in organization).

C. Federal Reserve Bank of St. Louis (Randall C. Sumner, Vice President) 411 Locust Street, St. Louis, Missouri 63166-2034:

1. *Southern Trust Bancshares, Inc.*, Goreville, Illinois; to become a bank holding company by acquiring 100 percent of the voting shares of SouthernTrust Bank, Goreville, Illinois (in organization).

D. Federal Reserve Bank of Kansas City (Donna J. Ward, Assistant Vice President) 925 Grand Avenue, Kansas City, Missouri 64198-0001:

1. *Frontier Management LLC, and Frontier Holdings, LLC*, both of Madison, Nebraska; to become bank holding companies by acquiring 100 percent of the voting shares of Bank of Madison, Madison, Nebraska.

E. Federal Reserve Bank of San Francisco (Tracy Basinger, Director, Regional and Community Bank Group) 101 Market Street, San Francisco, California 94105-1579:

1. *Western Sierra Bancorp*, Cameron Park, California; to acquire 100 percent of the voting shares of Gold Country Financial Services, Inc., Marysville, California, and thereby indirectly acquire Gold County, N.A., Marysville, California.

Board of Governors of the Federal Reserve System, January 21, 2005.

Robert deV. Frierson,

Deputy Secretary of the Board.

[FR Doc. 05-1429 Filed 1-25-05; 8:45 am]

BILLING CODE 6210-01-S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Amendment To Extend for One Year the January 24, 2003, Declaration Regarding Administration of Smallpox Countermeasures, as Amended on January 24, 2004

AGENCY: Office of the Secretary (OS), Department of Health and Human Services (DHHS).

ACTION: Notice.

SUMMARY: Concern that terrorists may have access to the smallpox virus and attempt to use it against the American public and United States Government facilities abroad continues to exist. The January 24, 2003, declaration regarding administration of smallpox countermeasures, as amended on January 24, 2004, is extended for one year until and including January 23, 2006.

DATES: This Notice is effective as of January 24, 2005.

FOR FURTHER INFORMATION CONTACT: William F. Raub, Ph.D., Principal Deputy Assistant Secretary for the Office of Public Health and Emergency Preparedness, 200 Independence Avenue, SW., Washington, DC 20201, Telephone (202) 690-7383 (this is not a toll-free number).

SUPPLEMENTARY INFORMATION: Section 224(p) of the Public Health Service Act, which was established by section 304 of the Homeland Security Act of 2002 and amended by section 3 of the Smallpox Emergency Personnel Protection Act of 2003 ("SEPPA"), is intended to alleviate certain liability concerns associated with administration of smallpox countermeasures and, therefore, ensure that the countermeasures are available and can be administered in the event of a smallpox-related actual or potential public health emergency such as a bioterrorist incident.

On January 24, 2003, due to concerns that terrorists may have access to the smallpox virus and attempt to use it against the American public and U.S. Government facilities abroad, the Secretary issued a declaration making section 224's legal protections available. The declaration was effective until and including January 23, 2004. On January 24, 2004, the Secretary amended the definitions contained in the January 24, 2003 declaration in light of the statutory amendments in section 3 of SEPPA because such definitions were no longer appropriate, and extended the declaration for one year until January 23, 2005. Pursuant to section 224(p)(2)(A), the Secretary issues the amendment below to extend for one year up to and including January 23, 2006 the January 24, 2003 declaration, as amended.

Amendment To Extend January 24, 2003 Declaration, as Amended, Regarding Administration of Smallpox Countermeasures

I. Policy Determination

The underlying policy determinations of the January 24, 2003 declaration continue to exist, including the heightened concern that terrorists may

have access to the smallpox virus and attempt to use it against the American public and U.S. Government facilities abroad.

II. Amendment of Declaration

I, Claude A. Allen, Acting Secretary of the Department of Health and Human Services, have concluded, in accordance with the authority vested in me under section 224(p)(2)(A) of the Public Health Service Act, that a potential bioterrorist incident makes it advisable to extend the January 24, 2003 declaration, as amended, regarding administration of smallpox countermeasures until and including January 23, 2006. The January 24, 2003, declaration, as amended, may be further amended as circumstances require.

III. Effective Dates

This extension is effective January 24, 2005 until and including January 23, 2006. The effective period may be extended or shortened by subsequent amendment to the January 24, 2003, declaration.

Dated: January 21, 2005.

Claude A. Allen,
Acting Secretary.

[FR Doc. 05-1479 Filed 1-25-05; 8:45 am]

BILLING CODE 4120-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Clinical Laboratory Improvement Advisory Committee

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Public Law 92-463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting.

Name: Clinical Laboratory Improvement Advisory Committee (CLIAC).

Times and Dates:

8:30 a.m.–5 p.m., February 16, 2005.

8:30 a.m.–3 p.m., February 17, 2005.

Place: Doubletree Hotel (Atlanta/Buckhead), 3342 Peachtree Rd. NE., Atlanta, Georgia 30326, Telephone: (404) 231-1234.

Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 100 people.

Purpose: This committee is charged with providing scientific and technical advice and guidance to the Secretary of Health and Human Services, the Assistant Secretary for Health, and the Director, CDC, regarding the need for, and the nature of, revisions to the standards under which clinical laboratories are regulated; the impact on medical and laboratory practice of proposed revisions to

the standards; and the modification of the standards to accommodate technological advances.

Matters To Be Discussed: The agenda will include updates from the Food and Drug Administration, the Centers for Medicare & Medicaid Services, and the Centers for Disease Control and Prevention; implementation of cytology proficiency testing for individuals; a report from the CLIAC Workgroup on Good Laboratory Practices for Waived Testing, and discussion of the Workgroup's proposals related to such; and an introduction to appropriate quality control for diverse and evolving test systems, including microbiology identification systems. Agenda items are subject to change as priorities dictate.

Providing Oral or Written Comments: It is the policy of CLIAC to accept written public comments and provide a brief period for oral public comments whenever possible. *Oral Comments:* In general, each individual or group requesting to make an oral presentation will be limited to a total time of five minutes (unless otherwise indicated). Speakers must also submit their comments in writing for inclusion in the meeting's Summary Report. To assure adequate time is scheduled for public comments, individuals or groups planning to make an oral presentation should, when possible, notify the contact person below at least one week prior to the meeting date. *Written Comments:* For individuals or groups unable to attend the meeting, CLIAC accepts written comments until the date of the meeting (unless otherwise stated). However, the comments should be received at least one week prior to the meeting date so that the comments may be made available to the Committee for their consideration and public distribution. Written comments, one hard copy with original signature, should be provided to the contact person below. Written comments will be included in the meeting's Summary Report.

Contact Person for Additional Information: Rhonda Whalen, Chief, Laboratory Practice Standards Branch, Division of Laboratory Systems, Office of Public Health Partnerships, CDC, 4770 Buford Highway, NE, Mailstop F-11, Atlanta, Georgia 30341-3717; telephone (770) 488-8042; fax (770) 488-8279; or via e-mail at RWhalen@cdc.gov.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** Notices pertaining to announcements of meetings and other committee management activities, for CDC and the Agency for Toxic Substances and Disease Registry.

Dated: January 20, 2005.

Alvin Hall,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 05-1390 Filed 1-25-05; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Advisory Committee on Immunization Practices

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Public Law 92-463), the Centers for Disease Control and Prevention (CDC) announce the following Federal Committee meeting.

Name: Advisory Committee on Immunization Practices (ACIP).

Times and Dates:

8 a.m.–6:30 p.m., February 10, 2005.

8 a.m.–4:30 p.m., February 11, 2005.

Place: Atlanta Marriott Century Center, 2000 Century Boulevard, N.E., Atlanta, Georgia 30345-3377.

Status: Open to the public, limited only by the space available.

Purpose: The Committee is charged with advising the Director, CDC, on the appropriate uses of immunizing agents. In addition, under 42 U.S.C. 1396s, the Committee is mandated to establish and periodically review and, as appropriate, revise the list of vaccines for administration to vaccine-eligible children through the Vaccines for Children (VFC) program, along with schedules regarding the appropriate periodicity, dosage, and contraindications applicable to the vaccines.

Matters To Be Discussed: The agenda will include discussions on Hepatitis B vaccine recommendations; recommendations of use of Hepatitis A vaccine; Human Papilloma Virus vaccine working group update; Meningococcal conjugate vaccine and possible VFC vote on meningococcal vaccine use if the vaccine is licensed; varicella prevention; influenza vaccine recommendations for 2005; pertussis vaccine booster dose policy; polio outbreak response and stockpile planning; revisions to the general recommendations; yellow fever vaccine safety work group update; proposal for use of Evidence-based recommendations; rotavirus vaccine update; and Departmental updates.

Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Demetria Gardner, Epidemiology and Surveillance Division, National Immunization Program, CDC, 1600 Clifton Road, NE., (E-61), Atlanta, Georgia 30333, telephone (404) 639-8096, fax (404) 639-8616.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both the CDC and ATSDR.